NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT06072781 2026-04-02
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
NCT05787561 2026-03-12
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06394804 2026-02-03
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT06682572 2025-12-17
RAMP201J
Verastem, Inc.
Phase 2 Active not recruiting
NCT05512208 2025-10-22
DURAFAK
University of Oklahoma
Phase 2 Recruiting
NCT04625270 2025-01-29
RAMP 201
Verastem, Inc.
Phase 2 Active not recruiting
NCT03287271 2024-08-12
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Phase 1/2 Recruiting
NCT02943317 2019-04-30
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Verastem, Inc.
Phase 1 Terminated
NCT01778803 2017-05-17
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Verastem, Inc.
Phase 1 Completed